Recent interest in the M 1 muscarinic acetylcholine (ACh) receptor (mAChR) has led to the discovery of various selective agonists for the receptor. The novel selective agonist 1-(19-(2-methylbenzyl)-1,49-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1 (TBPB) displays unprecedented functional selectivity at the M 1 mAChR. This functional selectivity has been described to stem from sole interaction with an allosteric site, although the evidence for such a mechanism is equivocal. To delineate TBPB's mechanism of action, several truncated variants of TBPB were synthesized and characterized. Binding experiments with [
Introduction
The muscarinic acetylcholine (ACh) receptors (mAChRs) are prototypical rhodopsin-like G protein-coupled receptors that mediate a range of physiologic processes within the central nervous system and the periphery. Of the five mAChR subtypes, the M 1 mAChR is involved in cognition and memory (Langmead et al., 2008b) , and is a promising therapeutic target for treating a range of disorders such as Alzheimer's disease and schizophrenia. Indeed, the M 1 /M 4 mAChR-preferring agonist xanomeline showed clinically positive outcomes in studies of patients with both disorders (Bodick et al., 1997; Shekhar et al., 2008) . However, the high occurrence of adverse side effects in subjects, attributed predominantly to actions at peripheral M 2 and M 3 mAChRs, exemplifies the challenge of developing subtypeselective compounds that target the highly homologous AChbinding (orthosteric) site shared across the mAChR family.
Allosteric modulation of mAChRs is now well appreciated (Clark and Mitchelson, 1976; Stockton et al., 1983; Christopoulos et al., 1993; Conn et al., 2009) . Upon binding to a site on the receptor that is topographically distinct from the orthosteric site, allosteric ligands modulate orthosteric ligand affinity and/or efficacy. Allosteric sites can also be less conserved across a G protein-coupled receptor family, offering potential to develop subtype-selective compounds (Keov et al., 2011) . As such, recent studies have discovered several highly subtypeselective mAChR allosteric modulators (Chan et al., 2008; Ma et al., 2009; Marlo et al., 2009 ).
In the search for selective activators of the M 1 mAChR, a number of ligands have been classified as "allosteric" agonists (Spalding et al., 2002; Jones et al., 2008; Langmead et al., 2008a; Lebois et al., 2010) . However, whether these compounds convey their actions solely via an allosteric site or via interaction with the orthosteric site remains uncertain. One such recently identified M 1 mAChR-selective agonist, 11-(19-(2-methylbenzyl)-1,49-bipiperidin-4-yl)-1H-benzo [d] imidazol-2(3H)-1 (TBPB) (Fig. 1) , displays high functional selectivity for the M 1 mAChR, yet the current evidence to support an allosteric mode of action remains equivocal. For example, previously reported noncompetitive antagonism between TBPB and atropine observed in a calcium mobilization assay may reflect a hemiequilibrium state (Charlton and Vauquelin, 2010) rather than allostery. Similarly, functional insensitivity of TBPB to mutation of the orthosteric residue Y381
6.51 A (Ward et al., 1999; Jones et al., 2008 ) may be reconciled with either an allosteric mode of binding or simply a different binding pose within the orthosteric pocket. Importantly, TBPB has been shown to retard the dissociation of the orthosteric antagonist [ (Jacobson et al., 2010) , which is an important hallmark of allosteric interaction. However, this assay reflects interaction of a test ligand on a receptor that has been pre-equilibrated with an orthosteric antagonist; although suggesting that TBPB can adopt an allosteric pose under such a circumstance, it does not guarantee that the ligand will adopt an allosteric mode of binding if the orthosteric site is unoccupied (Avlani et al., 2010) .
Similar behaviors have been reported of the M 1 mAChRselective agonists 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chloride (AC-42) and 1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone (77-LH-28-1) (Spalding et al., 2002; Langmead et al., 2008a) . We have demonstrated that AC-42 and 77-LH-28-1, despite not engaging with some amino acid residues required by prototypical agonists, can occupy the orthosteric domain of the M 1 and M 2 mAChRs in addition to, or simultaneously with, the allosteric site via a bitopic mechanism (May et al., 2007; Avlani et al., 2010) . Such a mechanism was first demonstrated for 4-(N-(3-chlorophenyl)carbamoyloxy)-2-butynyltrimethylammonium chloride at the M 2 mAChR. We previously adopted a reverse engineering approach to delineate its mechanism, by truncating McN-A-343 to identify distinct orthosteric and allosteric pharmacophores (Valant et al., 2008) .
Given the potential mixed orthosteric/allosteric characteristics of TBPB, similar to AC-42 and 77-LH-28-1, we hypothesized that TBPB is a bitopic ligand, rather than a pure allosteric agonist. Recent studies by Digby et al. (2012) and Sheffler et al. (2013) have made similar proposals, but remained unclear as to whether this mechanism involved concomitant binding to both orthosteric and allosteric sites, or acting as pure allosteric ligands at low concentrations and recognizing the orthosteric site only at higher concentrations. Such distinctions are important, because ascertaining differences between classes of ligands at the preclinical stage of discovery is vital in improving the likelihood of clinical translation of such molecules. Thus, to investigate this for TBPB, we adopted a reverse engineering approach. We provide evidence consistent with TBPB interacting concomitantly with orthosteric and allosteric sites in a bitopic mode of action, and show distinct structural moieties required by TBPB for interaction with the orthosteric binding domain and an allosteric site at the M 1 mAChR.
Materials and Methods
Chinese hamster ovary (CHO) Flp-In cells and Fluo-4-AM were purchased from Invitrogen (Carlsbad, CA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were from Gibco (Gaithersburg, MD) and JRH Biosciences (Lenexa, KS), respectively. The AlphaScreen SureFire phospho-extracellular signal-regulated kinase 1 and 2 (ERK1/2) reagents were donated by Drs. Michael Crouch and Ron Osmond (TGR Biosciences, Thebarton, SA, Australia). The AlphaScreen streptavidin donor beads and anti-IgG (protein A) acceptor beads used for phosphorylated ERK1/2 detection and [ Keov et al. at ASPET Journals on October 13, 2017 molpharm.aspetjournals.org Downloaded from (VCP813), were synthesized in-house as described in the Supplemental Methods. All other chemicals were from Sigma-Aldrich (St. Louis, MO).
cDNA Constructs and Generation of Stable Cell Line. cDNA encoding the wild-type human M 1 (M 1 ) mAChR was obtained from the Missouri University of Science and Technology (http://www.cdna.org) and was provided in pcDNA3.11. Sequence of the human M 1 mAChR was amplified by polymerase chain reaction and cloned into the Gateway entry vector pENTR/D-TOPO, using the pENTR directional TOPO cloning kit, according to the manufacturer's instructions (Invitrogen). The construct was subsequently transferred into the Gateway destination vector pEF5/frt/V5/dest using the LR Clonase enzyme mix (Invitrogen), and the constructs were used to transfect Flp-In CHO cells (Invitrogen) as described previously (May et al., 2007) . Cells were selected using 600 mg/ml (for the M 1 mAChR) hygromycin B (Roche, Basel, Switzerland) to generate cell lines stably expressing each receptor construct. Cells expressing the wild-type human M 2 , M 3 , and M 4 mAChRs were generated previously (May et al., 2007; Nawaratne et al., 2008; Stewart et al., 2010) .
Cell Culture and Membrane Preparations. Cells were maintained and cultured in high-glucose DMEM (Gibco) containing 10% FBS, 16 mM HEPES, and 600 mg/ml hygromycin B at 37°C under a humidified atmosphere containing 5% CO 2 . Membranes of cells expressing the M 1 , M 2 , M 3 , and M 4 mAChR were generated as previously described (Nawaratne et al., 2008) , except that the final pellet was resuspended in 5 ml of buffer (20 mM HEPES, 0.1 mM EDTA, pH7.4).
Radioligand Binding Assays. Binding assays were conducted as per Valant et al. (2008) H]NMS for 60 minutes at 37°C, followed by dissociation of the bound radioligand initiated with atropine (10 mM) alone or in the presence of a single concentration of each ligand-TBPB (100 mM), VCP813 (300 mM), VCP794 (100 mM), or heptane-1,7-bis-[dimethyl-39-phthalimidopropyl]-ammonium bromide (C 7 /3-phth; 100 mM)-added in a reverse time course protocol at time points ranging from 1 to 15 minutes.
Nonspecific binding was determined in the presence of 10 mM atropine for all studies. Reactions were terminated by rapid filtration onto GF/B grade filter paper (Whatman, Maidstone, UK) using a Brandel harvester, followed by three washes with ice-cold NaCl (0.9%). Radioactivity was determined via liquid scintillation counting.
Measurement of Intracellular ERK1/2 Phosphorylation. For all experiments, cells were seeded onto transparent 96-well cell culture plates at 4 Â 10 4 cells per well for M 1 -mAChR expressing cells and 3 Â 10 4 cells per well for cells expressing M 2 , M 3 , and M 4 mAChRs. Cells were grown overnight until confluent. Stimulation of ERK1/2 phosphorylation was determined using the AlphaScreen ERK1/2 SureFire protocol (TGR Biosciences). Prior to assay, cells were washed twice with 200 ml of phosphate-buffered saline and incubated in serum-free DMEM (supplemented with 16 mM HEPES) for at least 4 hours at 37°C in 5% CO 2 . The assay was performed at 37°C followed by addition of ligand to cells to a final volume of 200 ml. Time course experiments were initially performed to determine the time at which maximal ERK1/2 phosphorylation occurred following agonist stimulation. For subsequent agonist-stimulated concentration-response experiments, cells were incubated with each agonist for the time required to achieve peak response (3-5 minutes). For functional interaction studies, concentration-response curves were constructed for ACh in the absence and presence of varying concentrations of the reference orthosteric antagonist atropine, TBPB, or VCP813. Compounds were preincubated for 30 minutes prior to the addition of ACh, except when intrinsic agonism was detected, whereby coaddition with ACh was conducted instead.
Ligand-stimulated ERK1/2 phosphorylation was terminated by removal of media and drugs, followed by the addition of 100 ml of SureFire lysis buffer per well and agitation of lysates for 5 minutes at room temperature. Five microliters of this lysate was added in a 384-well white ProxiPlate (PerkinElmer). A mixture of SureFire activation buffer, SureFire reaction buffer, and AlphaScreen beads was prepared in a ratio of 100:600:3 (v/v/v) and added to the lysate for a lysate:mixture ratio of 5:8 (v/v). Plates were incubated for 1-1.5 hours at 37°C before the florescence signal was measured on a Fusion-a plate reader (PerkinElmer) using standard AlphaScreen settings.
For all experiments, 10% FBS was used as an internal positive control to stimulate phosphorylated ERK1/2 (peak response at 3 minutes for M 1 mAChR or 5 minutes for other subtypes), whereas vehicle was used as a negative control.
Intracellular Calcium Mobilization. Cells expressing the M 1 mAChR were cultured overnight on transparent 96-well cell culture plates at 4 Â 10 4 cells per well. At the time of assay, cells were washed once using HEPES-buffered saline (HBS) solution (150 mM NaCl, 2.2 mM CaCl 2 , 2.6 mM KCl, 1.18 mM MgCl 2 , 10 mM HEPES, 10 mM D-glucose) containing 0.5% bovine serum albumin (BSA) and 4 mM Probenecid, at pH 7.4. Cells were then treated with (1 mM) Fluo-4-AM (in HBS/BSA/Probenecid) for 60 minutes at 37°C in 5% CO 2 in the dark. Cells were then further washed (2 times) and placed in 180 ml of HBS/BSA/Probenecid solution. Ligands were added to cells in a FLEXstation 3 plate reader (Molecular Devices, Sunnyvale, CA). For interaction studies, ligands were added simultaneously to cells. Ca 21 /Fluo-4 fluorescence was then measured in the FLEXstation at an excitation wavelength of 485 nm and an emission wavelength of 525 nm, for 100 seconds (16 seconds prior to and 84 seconds following the addition of ligand) at 37°C.
Data Analysis. All data were analyzed using GraphPad Prism 5.02 (GraphPad Software, San Diego, CA). For radioligand saturation binding data, nonspecific and total binding data were globally fitted to the following equation (eq. 1):
where Y is the total binding, B max is the total receptor density, [A] is the radioligand concentration, K D is the equilibrium dissociation constant of radioligand, and NS is nonspecific radioligand binding. Data were expressed as picomoles of bound radioligand per milligram of protein. pK D 6 S.E. and B max 6 S.E. values were determined from three separate experiments performed in triplicate. For radioligand inhibition binding experiments, data sets for each ligand were fitted to a one-site binding equation and two-site binding equation to estimate inhibitor potency, followed by F-test analysis to determine which equation best fit the data (Nawaratne et al., 2008) . Equilibrium dissociation constant values, K i , were subsequently derived from inhibition binding experiments using the ChengPrusoff equation (Cheng and Prusoff, 1973) .
For radioligand dissociation kinetics experiments, data sets for each treatment were fitted to a single-phase exponential decay equation (May et al., 2007) , with estimated dissociation rate constants (K off ) statistically compared with incubation with atropine alone via F test.
Agonist concentration-response curves from intracellular calcium ([Ca 21 ] i ) mobilization and ERK1/2 phosphorylation experiments were fitted to the four-parameter-logistic equation to derive estimates for agonist potencies (pEC 50 ) and maximal agonist responses (E max ). For
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antagonist-mediated agonist concentration-response curve shifts, data of concentration-response curves in the absence and presence of antagonist were fitted to a Schild regression analysis (Arunlakshana and Schild, 1959) .
The quantification of signaling bias was determined by nonlinear regression analysis of agonist concentration-response curves of [Ca 21 ] i mobilization and ERK1/2 phosphorylation, using a form of the operational model of agonism as described by Kenakin et al. (2012) and Kenakin and Christopoulos (2013) 
where E m is the maximal attainable system response for the given pathway, basal is the level of response in the absence of agonist, t is defined by the ratio of the total concentration of receptors to the concentration of agonist receptor-complex that produces half the maximal system response, K A denotes the functional equilibrium dissociation constant of the agonist for the receptor, and n is the slope of the transducer function that links occupancy with response. The ratio of t/K A [determined as a single-fitted parameter 2 the logarithm log 10 (t/K A )] is referred to herein as the "transduction coefficient," and incorporates both the affinity of the agonist for the active (signaling) state of the receptor and the efficiency of receptor coupling to signaling mechanisms. Following estimation of the transduction coefficient for each agonist at each signaling pathway, the log 10 (t/K A ) values were normalized to that determined for the endogenous agonist ACh within each signaling pathway, to cancel cell-dependent effects on the agonism observed for each pathway. This yields a "normalized transduction coefficient," denoted as Dlog 10 (t/K A ), calculated as:
The determination of a ligand's actual agonist bias toward one pathway (j1) over another (j2) is given as:
where eq. 5:
Biased signaling is detected when bias values are significantly different from 1, otherwise observed when log 10 (Bias) values are significantly different from zero. Due to the determination of composite parameters, the associated propagation of error in eqs. 3-5 was accounted for through application of the following equation:
Statistical analyses were performed, as appropriate, using Student's t test or one-way analysis of variance with Dunnett's or Bonferroni's post tests, and significance taken as P , 0.05.
Results
Evidence for Competitive Interaction with the Orthosteric Binding Site by TBPB. The binding of TBPB to membranes of Flp-In CHO cells expressing the M 1 mAChR was investigated using equilibrium binding studies. TBPB inhibited, in a concentration-dependent manner, the binding of 1.0 nM [ 3 H]NMS (pK D 5 8.93 6 0.09) from the M 1 mAChR ( Fig. 2A) , as did ACh. This behavior is consistent with a competitive mode of interaction with the receptor, with the displacement of radioligand similar to that of the orthosteric ligands, ACh, and atropine. As such, the data were empirically fitted to a one-site inhibitory mass action curve to determine potency (IC 50 ) estimates, followed by conversion to equilibrium binding dissociation constant estimates (Table 1) . K D concentration of radioligand in the presence of 100 mM (GppNHp) at 37°C for 1 hour (M 1 ) or 30°C for 1.5 hours (M 2 -M 4 ). Nonspecific binding was determined using 10 mM atropine. Data are plotted as the mean 6 S.E. from three to nine independent experiments.
The ability of TBPB to bind to other mAChR subtypes was also investigated. Equilibrium binding studies conducted on membranes expressing the M 2 , M 3 , and M 4 mAChRs revealed TBPB-mediated inhibition of [ 3 H]NMS binding at all subtypes investigated (Fig. 2, B-D) . The binding affinities of TBPB estimated at these subtypes were also comparable, with an approximately 3-fold maximal divergence (M 1 versus M 2 ).
We next studied the functional activity of TBPB at the M 1 , M 2 , M 3 , and M 4 mAChRs. Despite differences in Ga subtype coupling preferences, activation of each of the M 1 -M 4 mAChR subtypes results in convergent signaling to ERK1/2 phosphorylation (Crespo et al., 1994; Rosenblum et al., 2000) . Hence, we chose to investigate mAChR-mediated ERK1/2 phosphorylation. As expected, TBPB robustly activated M 1 mAChR-mediated phosphorylation of ERK1/2 ( Fig. 3A ; Table 2 ). TBPB failed to elicit responses at the M 2 and M 3 mAChRs, but behaved as a weak partial agonist at the M 4 mAChR subtype, mediating ERK1/2 phosphorylation with submicromolar potency, comparable to its affinity previously estimated at this subtype (Fig. 3, B-D) .
Given the lack of agonist activity of TBPB at the M 2 and M 3 mAChRs and reduced efficacy observed at the M 4 subtype, we investigated the antagonist properties of this ligand (Fig. 4) . Consistent with the competitive-like displacement of [ 3 H]NMS observed at these receptors, TBPB antagonized AChmediated responses, characterized by a parallel, dextral displacement of the endogenous agonist's concentrationresponse curve. TBPB antagonism of ACh at the M 2 and M 3 mAChR was well fitted by the Schild model, with the estimated Schild slopes close to unity (Table 3) .
Evidence for Interaction with an Allosteric Site by TBPB. Although we have found evidence for TBPB competitively interacting with the orthosteric ligands of mAChRs, we examined whether TBPB could also interact allosterically with the M 1 mAChR, as per its initial classification as an allosteric agonist . Kinetic binding experiments are perhaps the best suited experiments to confirm allosteric interactions (Christopoulos et al., 1998 Characterization of a Bitopic Mode of Action of TBPB pharmacology of TBPB suggests that this novel ligand could be bitopic. We have previously adopted a reverse engineering approach to elucidate the roles of structural moieties for the binding and function of the bitopic agonist, McN-A-343, at the M 2 mAChR (Valant et al., 2008) ; therefore, we truncated TBPB to further investigate its mechanism of action at the M 1 mAChR. A range of fragment molecules were synthesized representing truncations from both the "upper" ortho-tolyl end and "lower" benzimidazolone end of TBPB. These fragments were subsequently screened for their abilities to activate or antagonize M 1 mAChR-mediated [Ca 21 ] i mobilization and ERK1/2 phosphorylation in Flp-In CHO cells, from which two fragment compounds were identified, VCP794 and VCP813, each representing truncation from either the ortho-tolyl end or the benzimidazolone end, respectively (Fig. 1) .
VCP794 exhibited robust agonist activity for both [Ca 21 ] i mobilization and ERK1/2 phosphorylation, maximally activating receptor-mediated responses to the same levels as the endogenous agonist ACh and the parent molecule TBPB (Fig. 6,  A and B) . When comparing the potency values of each agonist between the two different functional outputs, it appeared that all three agonists, ACh, TBPB, and VCP794, exhibited bias toward [Ca 21 ] i mobilization relative to ERK1/2 phosphorylation. However, intriguingly, whereas VCP794 exhibited approximately a 3-fold lower potency than TBPB in [Ca 21 ] i mobilization experiments, the fragment compound displayed an approximately 3-fold higher potency than TBPB in ERK1/2 phosphorylation experiments. Such reversal of potency values is indicative of biased agonism, meaning the agonist fragment of TBPB, VCP794, appeared less biased toward the [Ca 21 ] i mobilization pathway relative to the ERK1/2 pathway when compared with the parent compound.
The normalized responses of each agonist for the activation of [Ca 21 ] i mobilization and ERK1/2 phosphorylation, at equimolar concentrations, were replotted against each other to construct a bias plot ( Fig. 6C ; Gregory et al., 2010) . From this, an evident difference in the profile of VCP794 was observed, reflecting the agonist's greater preference for ERK1/2 phosphorylation relative to ACh and TBPB. Complementing this qualitative visualization of bias, a quantitative measure of bias was determined through application of an operational model of agonism (eq. 2) to the agonist concentration-response curves of these three agonists from both of these assays (Evans et al., 2011; Kenakin et al., 2012) . This provided quantification of the transduction coefficient of each agonist for signal transduction in the system. These values are compiled in ] i mobilization transduction coefficient and the transduction coefficient for ERK1/2 phosphorylation is depicted in Fig. 6D . Statistical comparison of the bias factors for the three agonists found significant differences between the bias factor of VCP794 and those of ACh and TBPB, whereas no significant difference was Negative logarithm of the molar concentration of antagonist that makes it necessary to double the concentration of agonist needed to elicit the original response. determined between the values of ACh and TBPB (P , 0.05, one-way analysis of variance, post-hoc Bonferroni test).
In contrast, VCP813 did not exhibit any agonism for [Ca 21 ] i mobilization and ERK1/2 phosphorylation responses at the M 1 mAChR. Subsequent interaction studies screening nonagonist fragment compounds revealed that VCP813 exhibited appreciable antagonism of ACh responses in both signaling outputs studied (Fig. 7, A and B) . This concentrationdependent reduction in ACh potency by VCP813 was well fitted by the Schild model, and allowed us to estimate the functional affinity of VCP813 (pA 2 5 5.54 6 0.04, Schild slope 5 1.14 6 0.03).
Evidence for a Competitive Mode of Interaction by Fragments of TBPB. The identification of VCP813 as an antagonist afforded more extensive investigation into the mode of binding of this fragment compound through further functional interaction studies. Given the appreciable conservation of the molecular structure of its parent, it is probable that VCP813 interacts with the same novel binding domain as TBPB. As such, functional interaction studies were performed to determine the effect of VCP813 on TBPB-mediated [Ca 21 ] i mobilization responses at the M 1 mAChR. As with ACh, TBPB was similarly antagonized by VCP813 (Fig. 7C) . Not only were the data of the dextral displacement of the TBPB concentration-response curve well fitted to the Schild model (pA 2 5 5.33 6 0.10, Schild slope 5 1.38 6 0.14), but the affinity estimate of VCP813 was also not significantly different from the estimated value from interaction studies with ACh in [Ca 21 ] i mobilization experiments (P . 0.05, Student's t test).
With the antagonism of ACh by VCP813 being consistent with a competitive mode of interaction with the orthosteric binding site, we sought to validate these observations through similar experiments with the orthosteric antagonist atropine on the [Ca 21 ] i mobilization elicited by ACh and TBPB (Fig. 7 , D and E). As expected, atropine competitively antagonized AChmediated responses at the receptor, the data being well fitted to the Schild model (pA 2 5 8.41 6 0.09, Schild slope 5 0.97 6 0.06). ]NMS for 60 minutes at 37°C, followed by dissociation of the bound radioligand initiated with atropine (10 mM) alone (control) or in the presence of the indicated compound. Data are depicted as the mean 6 S.E. from three to four independent experiments. *Significantly different from atropine alone; P , 0.05, F test. 
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In contrast to the atropine-mediated depression of the maximal response by TBPB , we did not observe any change in the maximal responses of TBPB by the classic orthosteric antagonist, consistent with competitive antagonism (pA 2 5 8.34 6 0.01, Schild slope 5 1.11 6 0.04). Further analysis found no significant difference between this affinity estimate and that determined from experiments with ACh (P . 0.05, Student's t test), corroborating the hypothesis that TBPB may interact with the orthosteric site as well as suggesting that VCP813 can either interact with the orthosteric binding domain of the receptor or, alternatively, interact allosterically with high negative cooperativity.
Given that TBPB does not bind exclusively to the M 1 mAChR, we extended the functional studies of its fragments to the M 2 , M 3 , and M 4 mAChRs (Fig. 8, A-C) . In comparison with the parent molecule, VCP794 activated both M 2 and M 4 mAChR-mediated ERK1/2 phosphorylation to the same maximum as ACh, but did not activate the M 3 mAChR. Subsequent interaction studies with ACh at the M 3 mAChR did not reveal any appreciable antagonism of ACh-mediated phosphorylated ERK1/2 phosphorylation response by VCP794 (data not shown). In the case of VCP813, similar to its profile at the M 1 mAChR, VCP813 did not exhibit agonist activity (Fig. 8 , A-C) but antagonized ACh-mediated responses at all three receptor subtypes (Fig. 8, D-F) . The antagonism of ACh by VCP813 fit well to the Schild model (Table 5) , consistent with a competitive interaction with the orthosteric agonist.
To better understand how these two fragment compounds engage with the mAChRs, additional equilibrium radioligand binding studies were conducted (Fig. 9) . As with its parent molecule, VCP794 displaced [ VCP813 Interacts Allosterically with the M 1 mAChR. Since VCP794 and VCP813 retain TBPB's ability to interact competitively with orthosteric ligands at the M 1 -M 4 mAChRs, we chose to investigate whether the molecular truncation of these ligands led to the subtraction of the parent's allosteric nature. We investigated [
3 H]NMS dissociation in the presence and absence of VCP794 (100 mM) and VCP813 (300 mM) (Fig. 10) . These experiments determined that VCP794 did not significantly retard radioligand dissociation from the receptor (K off 5 0.213 6 0.010 min 
Discussion
The interest in the M 1 mAChR as a therapeutic target has led to the recent identification of a range of selective agonists for this receptor (Spalding et al., 2002; Jones et al., 2008; Langmead et al., 2008a; Lebois et al., 2010) . Although the novel pharmacology of a number of these compounds has led to their classification as "allosteric" agonists, the evidence to support a purely allosteric mechanism of action for some of these compounds is equivocal (see Introduction). The M 1 mAChR-selective agonist TBPB is one such ligand, and herein we provide evidence, using a molecular truncation approach, of a likely interaction with the orthosteric binding domain of the M 1 mAChR and a putative bitopic mechanism of action.
TBPB and its fragments display similar affinity for the M 2 , M 3 , and M 4 subtypes compared with the M 1 mAChR, with a maximal difference of approximately 3-fold (except for VCP794 at the M 3 mAChR). Additionally, both TBPB and VCP813 competitively antagonize ACh-mediated responses, in agreement with previous findings with TBPB (Lebois et al., 2010) , suggesting that TBPB interacts with the highly homologous orthosteric binding domain of the receptor family. Interestingly, we also observed partial agonist activity of TBPB at the M 4 mAChR subtype, which has not been previously reported. This may explain the incomplete antagonism of ACh-stimulated activation of the M 4 mAChR observed by Lebois et al. (2010) , and likely reflects the sensitivity of the cellular/biologic system and endpoint studied compared with previous investigations. It also suggests TBPB exploits structural regions conserved between the M 1 and M 4 mAChR subtypes to elicit receptor activation. The apparently competitive behavior of TBPB argues against a purely allosteric mechanism of agonism at the M 1 mAChR. Indeed, consideration of the evidence for a purely allosteric mechanism of action by TBPB is somewhat inconclusive, with recent exploration of TBPB's structural activity relationships also uncovering competitive orthosteric pharmacology (Sheffler et al., 2013) . In contrast to initial observations of noncompetitive antagonism of TBPB by atropine , we observed competitive antagonism. Since we did not preequilibrate with atropine, this discrepancy likely reflects the limitations of nonequilibrium binding conditions of the assay (i.e., [Ca 21 ] i mobilization), whereby noncompetitive antagonism can result from hemiequilibria (Charlton and Vauquelin, 2010) . Additionally, although TBPB retains agonist activity at various mutant receptors of the M 1 mAChR in which key orthosteric residues had been substituted for alanine Jacobson et al., 2010) , an interaction with the orthosteric binding domain by TBPB cannot be rejected, as it may still interact with other residues of the binding site.
TBPB is, however, capable of interacting with an allosteric site at the M 1 mAChR, as evidenced by its alteration of the dissociation kinetics of the orthosteric radioligand [
3 H]NMS, demonstrated in our study and previously (Jacobson et al., 2010 ). Retardation of [ 3 H]NMS dissociation by the fragment, VCP813, further supports an allosteric mechanism. Despite truncation of the parent molecule, VCP813 interacts competitively at the receptor with TBPB. Hence, it is likely that these compounds, in addition to sharing molecular structure, share the same allosteric site. However, although the retardation of radioligand dissociation is unequivocal evidence of an allosteric site interaction on a receptor already occupied by an orthosteric ligand, this does not demonstrate whether TBPB prefers a purely allosteric mode of interaction with the free receptor. Indeed, this is a caveat to the detection of allosteric site interactions with this assay. Notably, the concentration of TBPB required to observe the allosteric effect on radioligand dissociation would likely saturate the receptor population in the absence of other ligands, based on our binding data. Additionally, a lower concentration of TBPB (50 mM) has been reported to have no effect on [ 3 H]NMS dissociation (Sheffler et al., 2013) , suggesting that a higher-affinity orthosteric/ bitopic interaction predominates over a much lower-affinity (purely) allosteric interaction. In support of this notion, the retardation of [ 3 H]NMS dissociation by the bitopic ligand McN-A-343, at the M 2 mAChR, has been defined at concentrations that are greater than its equilibrium dissociation constant (May et al., 2007; Valant et al., 2008) . Thus, our findings support an orthosteric mode of interaction for TBPB, in addition to an established allosteric pharmacology at the M 1 mAChR. This dual orthosteric/allosteric behavior is reconcilable with a bitopic mode of interaction.
Analysis of the pharmacological behavior of various fragments of TBPB provides insight into its mechanism of action from its molecular structure. In particular, the distal orthotolyl moiety is possibly necessary for interaction with an allosteric site of the M 1 mAChR, whereas the lower benzimidazolone end is required for interaction with the orthosteric site and receptor activation. In support of current beliefs is the finding that the fragment, VCP813, is able to retard [ 3 H]NMS dissociation, despite an approximately 100-fold lower potency to displace the radioligand compared with TBPB. Furthermore, the possession of this aromatic moiety seems indispensable for the selective agonist activity, but not affinity, of TBPB for the M 1 mAChR, as demonstrated by our binding studies at other mAChR subtypes. Additionally, we found that VCP813 antagonized both ACh and TBPB with similar apparent affinities in a competitive-like manner. It is probable that the fragment retains a portion of the orthosteric binding moiety, and is able to occupy part of the orthosteric binding domain similar to its parent molecule. Interestingly, VCP813 does not display appreciable binding selectivity for any mAChR subtype tested. It is possible that the allosteric domain engaged by the aromatic moiety of VCP813 (and TBPB), similar to several prototypical allosteric modulators for mAChRs (Ellis et al., 1991; Jakubík et al., 1995; Christopoulos et al., 1999) , is structurally similar across the mAChR family.
The pharmacology of VCP794 also supports a common allosteric domain for the aromatic moiety. First, the absence of the distal ortho-tolyl moiety in VCP794 results in a bias of signaling toward ERK1/2 phosphorylation as compared with [Ca 21 ] i mobilization, relative to ACh, which is "restored" with the addition of the aromatic functionality in TBPB. Differences in stimulus bias engendered through simultaneous engagement of an allosteric and orthosteric site have been observed for other bitopic compounds as compared with their corresponding orthosteric pharmacophore constituents. For example, investigation of bitopic agonists for the adenosine A 1 receptor has found a reversal of potencies between the stimulation of 59-O-(3-[ 35 S]thio)triphosphate binding and ERK1/2 phosphorylation relative to the individual orthosteric agonist component of the bitopic molecule (Narlawar et al., 2010) . Second, there is a marked loss of agonist selectivity of VCP794 for the M 1 mAChR over other mAChR subtypes that can be related to the absence of the distal ortho-tolyl moiety of TBPB. This is consistent with previous studies of analogs of the TBPB molecular scaffold that possess or lack a distal aromatic moiety Miller et al., 2008; Budzik et al., 2010) . It is noted that similar agonist studies have been previously conducted with VCP794 at each of the five mAChR subtypes, with a similar lack of subtype selectivity observed for the agonist (Budzik et al., 2010) . Intriguingly, VCP794 displays poor binding affinity for the M 3 mAChR, which likely contributes to the lack of agonism observed at this receptor. This affinity is "restored" with the aromatic orthotolyl group extension of TBPB.
Given our findings, we propose that the ortho-tolyl moiety of TBPB engages with a common spatial allosteric domain of the mAChR family, whereby the engagement of this site provides additional stabilizing contact(s) with the mAChRs (such as the M 3 subtype). Furthermore, the structural differences within and proximal to this site between mAChR subtypes may engender different degrees of (negative) allosteric modulation Characterization of a Bitopic Mode of Action of TBPB of the agonist portion of the molecule. Indeed, such a mechanism of modulation of a ligand's own agonist responses has been demonstrated for the bitopic ligand, McN-A-343, at the M 2 mAChR (Valant et al., 2008) . Consequently, this interaction with the orthosteric site of receptor is of importance for the translation and prediction of TBPB's pharmacology established in vitro to an in vivo setting. TBPB's orthosteric/ bitopic interaction may provide insight into its lack of in vivo efficacy in reversing scopolamine-induced memory deficits in mice (Ma et al., 2009) . Although activation of the M 1 mAChR is associated with memory and cognitive functions, a recent analysis of the antagonist occupancy of mAChRs in the brains of Rhesus macaques has suggested that blockade of M 2 mAChRs in the brain stem may also mediate memory deficits induced by muscarinic antagonists such as scopolamine (Yamamoto et al., 2011) . Therefore, it is possible that the antagonism of non-M 1 mAChR subtypes by TBPB may negate any potential beneficial effects from M 1 mAChR activation in scopolamine-treated rats (Ma et al., 2009) , with an analogous compound (with agonist activity at the other mAChR subtypes) able to reverse scopolamine-induced amnesia in rats (Budzik et al., 2010) .
In conclusion, our results are consistent with a dual orthosteric/allosteric pharmacology of TBPB, most parsimoniously described by a concomitantly orthosteric/allosteric bitopic mechanism of action at the M 1 mAChR. These findings can provide a basis for reassessing the classification of other functionally selective agonists deemed to be solely allosteric.
